Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS‐CoV) and its putative receptor, angiotensin‐converting enzyme 2 (ACE2)

Severe acute respiratory syndrome (SARS) is an emerging infectious disease associated with a new coronavirus, SARS‐CoV. Pulmonary involvement is the dominant clinical feature but extra‐pulmonary manifestations are also common. Factors that account for the wide spectrum of organ system involvement and disease severity are poorly understood and the pathogenesis of SARS‐CoV infection remains unclear. Angiotensin converting enzyme 2 (ACE2) has recently been identified as the functional cellular receptor for SARS‐CoV. Studies of the tissue and cellular distribution of SARS‐CoV, and ACE2 protein expression, reveal new insights into the pathogenesis of this deadly disease. ACE2 is expressed at high level in the primary target cells of SARS‐CoV, namely pneumocytes and surface enterocytes of the small intestine. Despite the fact that SARS‐CoV can infect the lung and intestine, the tissue responses in these two organs are different. All other tissues and cell types expressing ACE2 may be potential targets of SARS‐CoV infection. Remarkably, endothelial cells, which express ACE2 to a high level, have not been shown to be infected by SARS‐CoV. There is also evidence that cell types without detectable ACE2 expression may also be infected by the virus. Furthermore, studies in a new human cell culture model have indicated that the presence of ACE2 alone is not sufficient for maintaining viral infection. Therefore, other virus receptors or co‐receptors may be required in different tissues. Moreover, the interaction between SARS‐CoV and the immunological or lymphoid system remains to be defined. It is clear that we are only at the dawn of our understanding of the pathogenesis of SARS. As our knowledge of the pathogenic mechanisms improves, a more rational approach to therapeutic and vaccine development can be designed in order to combat this new and fatal human disease. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  J. Sung,et al.  Persistent infection of SARS coronavirus in colonic cells in vitro , 2004, Journal of medical virology.

[2]  B. Moss,et al.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Z. Lang,et al.  Pathological study on severe acute respiratory syndrome. , 2003, Chinese medical journal.

[4]  G. Tse,et al.  Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in‐situ hybridization study of fatal cases , 2004, The Journal of pathology.

[5]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[6]  Tae Woo Kim,et al.  Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus , 2004, Journal of Virology.

[7]  Ching-lung Lai,et al.  SARS‐associated viral hepatitis caused by a novel coronavirus: Report of three cases , 2004, Hepatology.

[8]  Sung Keun Kang,et al.  Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. , 2004, Science.

[9]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[10]  J. Sung,et al.  Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection , 2003 .

[11]  Guoping Zhao,et al.  Molecular Evolution of the SARS Coronavirus During the Course of the SARS Epidemic in China , 2004, Science.

[12]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[13]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[14]  J. Sung,et al.  Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS) , 2004, Journal of Clinical Pathology.

[15]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[16]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[17]  Y. Guan,et al.  Detection of SARS Coronavirus in Patients with Suspected SARS , 2004, Emerging infectious diseases.

[18]  D. Dimitrov,et al.  The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.

[19]  Xiaolei Yin,et al.  Expression cloning of functional receptor used by SARS coronavirus , 2004, Biochemical and Biophysical Research Communications.

[20]  Tzei-Yi Lin,et al.  Detection of Severe Acute Respiratory Syndrome–Associated Coronavirus in Pneumocytes of the Lung , 2004, American journal of clinical pathology.

[21]  K. Tao,et al.  Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine , 2004, Immunology Letters.

[22]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.

[23]  R. Rappuoli,et al.  SARS — beginning to understand a new virus , 2003, Nature Reviews Microbiology.

[24]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[25]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[26]  O. Tsang,et al.  Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong , 2003, Annals of Internal Medicine.

[27]  N. Nagata,et al.  Laboratory and Epidemiology Communications SARS Coronavirus-Infected Cells in Lung Detected by New In Situ Hybridization Technique , 2003 .

[28]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[29]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[30]  Junya Fukuoka,et al.  Lung pathology of severe acute respiratory syndrome (SARS): a study of 8 autopsy cases from Singapore , 2003, Human Pathology.

[31]  J. Sung,et al.  Association of Human-Leukocyte-Antigen Class I (B*0703) and Class II (DRB1*0301) Genotypes with Susceptibility and Resistance to the Development of Severe Acute Respiratory Syndrome , 2004, The Journal of infectious diseases.

[32]  Chi-kong Li,et al.  Inflammatory cytokine profile in children with severe acute respiratory syndrome. , 2004, Pediatrics.

[33]  K. Yuen,et al.  Genomic characterisation of the severe acute respiratory syndrome coronavirus of Amoy Gardens outbreak in Hong Kong , 2003, The Lancet.

[34]  C. Johnston,et al.  ACE2, a new regulator of the renin–angiotensin system , 2004, Trends in Endocrinology & Metabolism.

[35]  J. Loo,et al.  Association of HLA class I with severe acute respiratory syndrome coronavirus infection , 2003, BMC Medical Genetics.

[36]  W. Travis,et al.  Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. , 2004, Archives of pathology & laboratory medicine.

[37]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[38]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[39]  J. Zhan,et al.  Digestive system manifestations in patients with severe acute respiratory syndrome. , 2003, Chinese medical journal.